Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Blend · Baron (F/K/A Baron Asset )

Baron Opportunity Fund BARON OPPORTUNITY FUND (BIOPX)

Ticker BIOPX · Since 2000-02-29 · · Holdings as of Jun 30, 2026

Expense ratio
1.31%$131/yr per $10k
5-yr return
+9.8%annualized
1-yr return
+19.4%as of Dec 2025
Net assets
$2.1Ball share classes
Holdings
49

Bottom line

Is BIOPX a good fund? The bottom line

BIOPX is a share class of Baron Opportunity Fund, a managed large blend mutual fund from Baron (F/K/A Baron Asset ).

Annual fees run 1.31% — about $131 a year on every $10,000 invested, more expensive than 78% of large blend funds we track.

It returned +19.4% over one year, +9.8% a year over five years, +19.8% a year over ten (as of Dec 31, 2025, per its prospectus).

With $2.1 billion in net assets and 49 holdings, its largest position is Space Exploration Technologies Corp (19.0%) and the top 10 make up 63% of the portfolio.

What to watch

  • Expensive for its category (1.31%)
  • Concentrated: top 10 holdings are 63% of assets
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What BIOPX invests in

The investment goal of Baron Opportunity Fund (the Fund) is capital appreciation through investments primarily in growth companies that benefit from technology advances.

The Fund is a diversified fund that, under normal circumstances, invests primarily in equity securities of U.S. high growth businesses of any market capitalization selected for their capital appreciation potential. BAMCO, Inc. (BAMCO or the Adviser) may invest in companies in any sector or industry that it believes will benefit from innovations and advances in technology. The Adviser seeks to invest in businesses it believes have significant opportunities for growth, sustainable competitive advantages, exceptional management, and an attractive valuation.

From the fund's prospectus (filed Jan 28, 2026).

BIOPX performance

Fund calendar-year total returns, 2016–2025 2016: −4.8%; 2017: +40.5%; 2018: +8.1%; 2019: +40.3%; 2020: +88.8%; 2021: +12.0%; 2022: −43.0%; 2023: +49.6%; 2024: +39.9%; 2025: +19.4% −5% 2016 +41% 2017 +8% 2018 +40% 2019 +89% 2020 +12% 2021 −43% 2022 +50% 2023 +40% 2024 +19% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
BIOPX+19.4%+9.8%+19.8%
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full BIOPX performance history →

What BIOPX costs

On a $10,000 investment, BIOPX's 1.31% expense ratio costs about $131 a year. The prospectus estimates $1,579 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full BIOPX fee table →

BIOPX top 10 holdings

#Holding% of fund
1Space Exploration Technologies Corp19.02%
2NVIDIA Corp11.49%
3Broadcom Inc5.76%
4Amazon.com Inc5.35%
5Tesla Inc4.67%
6Alphabet Inc4.36%
7Eli Lilly & Co3.45%
8Spotify Technology SA3.35%
9Meta Platforms Inc2.81%
10Taiwan Semiconductor Manufacturing Co Ltd2.75%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 63% of the fund. See all top 25 holdings and asset mix →

Alternatives to BIOPX

More funds like BIOPX →

BIOPX FAQ

What is the expense ratio of BIOPX?
BIOPX's expense ratio is 1.31%, which works out to about $131 a year for every $10,000 invested. The prospectus estimates total costs of $1,579 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is BIOPX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.31%); concentrated: top 10 holdings are 63% of assets; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does BIOPX hold?
BIOPX's largest holdings are Space Exploration Technologies Corp (19.0%), NVIDIA Corp (11.5%), Broadcom Inc (5.8%), Amazon.com Inc (5.3%), Tesla Inc (4.7%). It holds 49 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is BIOPX's 5-year return?
BIOPX returned +9.8% a year over the five years ending Dec 31, 2025, and +19.8% a year over ten years. Past performance does not guarantee future results.
Who manages BIOPX?
BIOPX is offered by Baron (F/K/A Baron Asset ) through BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND).